In the past few years, growing clinical, immunological and histopathological evidence suggests that MOG-EM can now be considered as a clearly distinct disease entity from both multiple sclerosis (MS) and aquaporin-4-positive neuromyelitis optica spectrum disorder (NMOSD) [2–5]. This evidence concerns the gene AQP4 and myeloid sarcoma.